Treatments that generate higher number of adverse drug reactions and their symptoms

  1. Lucía Fernández-López 1
  2. Javier Navarro-Zaragoza 1
  3. María Falcón 1
  4. Aurelio Luna 1
  1. 1 Universidad de Murcia
    info

    Universidad de Murcia

    Murcia, España

    ROR https://ror.org/03p3aeb86

Journal:
Ars pharmaceutica

ISSN: 2340-9894,  0004-2927

Year of publication: 2015

Volume: 56

Issue: 4

Pages: 201-208

Type: Article

DOI: 10.4321/S2340-98942015000400003 DIALNET GOOGLE SCHOLAR lock_openOpen access editor

More publications in: Ars pharmaceutica

Abstract

Objectives: Adverse drug reactions (ADRs) are an important cause of morbidity and mortality worldwide and generate high health costs. Therefore, the aims of this study were to determine the treatments which produce more ADRs in general population and the main symptoms they generate. Methods: An observational, cross-sectional study consisting in performing a self-rated questionnaire was carried out. 510 patients were asked about the treatments, illnesses and ADRs, they had suffered from. Results: 26.7% of patients had suffered from some ADR. Classifying patients according to the type of prescribed treatment and studying the number of ADR that they had, we obtained significant differences (p ≤ 0.05) for treatments against arthrosis, anemia and nervous disorders (anxiety, depression, insomnia). Moreover, determining absolute frequencies of these ADRs appearance in each treatment, higher frequencies were again for drugs against arthrosis (22.6% of patients treated for arthrosis suffered some ADR), anemia (14.28%), nerve disorders (13.44%) and also asthma (16%). Regarding the symptoms produced by ADRs, the most frequent were gastrointestinal (60% of patients who suffered an ADR, had gastrointestinal symptoms) and nervous alterations (dizziness, headache, sleep disturbances etc) (24.6%). Conclusion: Therapeutic groups which produce more commonly ADRs are those for arthrosis, anemia, nervous disorders and asthma. In addition, symptoms which are generated more frequently are gastrointestinal and nervous problems. This is in accordance with the usual side effects of mentioned treatments. Health professionals should be informed about it, so that they would be more alert about a possible emergence of an ADR in these treatments. They also could provide enough information to empower patients and thus, they probably could detect ADR events. This would facilitate ADR detection and would avoid serious consequences generated to both patients' health and health economics.

Bibliographic References

  • Ahmad, A, Patel, I, Balkrishnan, R, Mohanta, GP, Manna, PK. (2013). An evaluation of knowledge, attitude and practice of Indian pharmacists towards adverse drug reaction reporting: A pilot study. Perspect Clin Res.. 4. 204-210
  • Peichen Sun, A, Kirby, B, Black, C, Helms, PJ, Bennie, M, Stuart McLay, J. (2014). Unplanned medication discontinuation as apotential pharmacovigilance signal: a nested young person cohort study. BMC Pharmacol Toxicol.. 15.
  • Bertulyte, I, Schwan, S, Hallberg, P. (2014). Identification of risk factors for carbamazepine-induced serious mucocutaneous adverse reactions: A case-control study using data from spontaneous adverse drug reaction reports. J Pharmacol Pharmacother.. 5. 100-38
  • Ahmadi, KR. (2011). Role of common genetic variants on the risk of Stevens-Johnson syndrome and toxic epidermal necrolysis. Pharmacogenomics. 12. 761-4
  • Khalili, H, Mohebbi, N, Hendoiee, N, Keshtkar, AA, Dashti-Khavidaki, S. (2012). Improvement of knowledge, attitude and perception of healthcare workers about ADR, a pre- and post-clinical pharmacists' interventional study. BMJ Open. 2.
  • Moore, N, Lecointre, D, Noblet, C, Mabille, M. (1998). Frequency and cost of serious adverse drug reactions in a department of general medicine. Br J CLin Pharmacol.. 45. 301-308
  • Vasen, Walter, Fiorentino, Roxana M. L. (2006). Farmacovigilancia: una herramienta poco utilizada. Medicina (B.Aires). 66. 257-262
  • Kyonen, ML, Folatre, BI, Zolezzi, RP, Badilla, MV, Marín, HF. (2006). Adverse reactions to L-asparaginase in children with acute lymphatic leukemia. Rev Méd Chile. 134. 1530-1534
  • Vergel Rivera, GM, Tasé Martínez, MJ, Groning Roque, E. (2009). Farmacología, proceso de atención en enfermería. 1. Editorial Ciencias Médicas. La Habana.
  • Herrera Carranza, J. (2003). Manual de Farmacia Clínica y Atención Farmacéutica. 1º. Elsevier. Madrid.
  • Faus Dáder, MJ, Amariles Muñoz, P, Martinez-Martinez, F. (2008). Atención Farmacéutica: conceptos, procesos y casos prácticos. 1. Ergon. Madrid.
  • Langerová, P, Vrtal, J, Urbánek, K.. (2014). Adverse Drug Reactions Causing Hospital Admissions in Childhood: A Prospective, Observational, Single-Centre Study. Basic Clin Pharmacol Toxicol..
  • Steinberg, I. (2000). Clinical choices of antibiotics: judging judicious use. Am J Manag Care. 6. S1178-88
  • Wattal, C, Goel, N, Khanna, S, Byotra, SP, Laxminarayan, R, Easton, A. (2015). Impact of informational feedback to clinicians on antibiotic-prescribing rates in a tertiary care hospital in Delhi. Indian J Med Microbiol.. 33. 255-9
  • Scaioli, G, Gualano, MR, Gili, R, Masucci, S, Bert, F, Siliquini, R. (2015). Antibiotic Use: A Cross-Sectional Survey Assessing the Knowledge, Attitudes and Practices amongst Students of a School of Medicine in Italy. PLoS One. 10.
  • Mittal, BV, Singh, AK. (2010). Hypertension in the developing world: challenges and opportunities. Am J Kidney Dis.. 55. 590-8
  • Schiffrin, EL. (2012). Hypertension: treatments, diabetes, and developing regions. Lancet. 380. 539-41
  • Soutello, AL, Rodrigues, RC, Jannuzzi, FF, São-João, TM, Martinix, GG, Nadruz, Jr W, Gallani, MC. (2015). Quality of Life on Arterial Hypertension: Validity of Known Groups of MINICHAL. Arq Bras Cardiol..
  • Kim, S, Hwang, J, Xuan, J, Jung, YH, Cha, HS, Kim, KH. (2014). Global metabolite profiling of synovial fluid for the specific diagnosis of rheumatoid arthritis from other inflammatory arthritis. PLoS One. 9.
  • Salido, M., Abásolo, L., Bañares, A. (2001). Revisión de los antiinflamatorios inhibidores selectivos de la ciclooxigenasa-2. Información Terapéutica del Sistema Nacional de Salud. 25.
  • Chaverri, F. JM. (2004). Antiinflamatorios No Esteroidales Ciclooxigenasa (COX) Selectivos: Efectividad y seguridad clínica: Más allá de la COX.
  • Cañás, M, Buschiazzo, H. (2001). Antiinflamatorios no esteroideos inhibidores específicos de la Ciclooxigenasa-2 (COX-2): Los Coxib. Femeba, Informe Area Farmacológica. 65. 8-10
  • González Perez, R, Poza Guedes, P, Vives, R, Canto, G. (2002). Antinflamatorios inhibidores selectivos de la cicloxigenasa-2 (COX-2). Alergol Inmunol Clin.. 17. 247-254
  • (2005). Comunicación sobre riesgos de medicamentos para profesionales sanitarios Ref: 2005/05: Nota informativa: Antiinflamatorios inhibidores selectivos de la COX-2 y riesgo cardiovascular: nuevas restricciones de uso.
  • Budnitz, DS, Pollock, DA, Weidenbach, KN, Mendelsohn, AB, Schroeder, TJ, Annest, JL. (2006). National surveillance of emergency department visits for outpatient adverse drug events. JAMA. 296. 1858-66
  • Clark, MA., Goheen, MM., Cerami, C. (2014). Influence of host iron status on Plasmodium falciparum infection. Front Pharmacol.. 5.
  • Sahebzamani, FM, Berarducci, A, Murr, MM. (2013). Malabsorption anemia and iron supplement induced constipation in post-Roux-en-Y gastric bypass (RYGB) patients. J Am Assoc Nurse Pract.. 25. 634-40
  • Pusatcioglu, C, Nemeth, E, Fantuzzi, G, Llor, X, Freels, S, Tussing-Humphreys, L. (2014). Systemic and tumor level iron regulation in men with colorectal cancer: a case control study. Nutr Metab.. 11.
  • (13 d). Vademecum.
  • Haefely, W, Martin, JR, Schoch, P. (1990). Novel anxiolytics that act as partial agonists at benzodiazepine receptors. Trends Pharmacol Sci.. 11. 452-6
  • Kostev, K, Rex, J, Eith, T, Heilmaier, C. (2014). Which adverse effects influence the dropout rate in selective serotonin reuptake inhibitor (SSRI) treatment?: Results for 50,824 patients. Ger Med Sci.. 12.
  • Haefely, W, Martin, JR, Schoch, P. (1990). Novel anxiolytics that act as partial agonists at benzodiazepine receptors. Trends Pharmacol Sci.. 11. 452-6
  • Rundfeldt, C1, Löscher, W. (2014). The pharmacology of imepitoin: the first partial benzodiazepine receptor agonist developed for the treatment of epilepsy. CNS Drugs. 28. 29-43
  • Faizi, M, Dabirian, S, Tajali, H, Ahmadi, F, Zavareh, ER, Shahhosseini, S, Tabatabai, SA. (2014). Novel agonists of benzodiazepine receptors: Design, synthesis, binding assay and pharmacological evaluation of 1,2,4-triazolo(1,5-a)pyrimidinone and 3-amino-1,2,4-triazole derivatives. Bioorg Med Chem..
  • Miyata, A, Iwamoto, K, Kawano, N, Kohmura, K, Yamamoto, M, Aleksic, B, Ebe, K, Noda, A, Noda, Y, Iritani, S, Ozaki, N.. (2014). The effects of acute treatment with ramelteon, triazolam, and placebo on driving performance, cognitive function, and equilibrium function in healthy volunteers. Psychopharmacology (Berl).
  • Vaswani, M, Linda, FK, Ramesh, S. (2003). Role of selective serotonin reuptake inhibitors in psychiatric disorders: a comprehensive review. Prog Neuropsychopharmacol Biol Psychiatry.. 27. 85-102
  • Yang, G, Chen, J, Xu, F, Bao, Z, Yao, Y, Zhou, J. (2014). Association between Tumor Necrosis Factor-α rs1800629 Polymorphism and Risk of Asthma: A Meta-Analysis. PLoS One. 9.
  • (Nove).
  • (Sept). National institute of health: National Heart, Lung and Blood Institute.
  • (2014). Pharmacovigilance Newsletter of Región of Murcia.
Data source: Dialnet